{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:32:29Z","timestamp":1762079549453,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.clbc.2016.08.005","type":"journal-article","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T06:20:35Z","timestamp":1472797235000},"page":"76-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens"],"prefix":"10.1016","volume":"17","author":[{"given":"Jennifer J.","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula R.","family":"Pohlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra M.","family":"Swain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2016.08.005_bib1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ccr.2010.06.014","article-title":"The therapeutic effect of anti- HER2\/neu antibody depends on both innate and adaptive immunity","volume":"18","author":"Park","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clbc.2016.08.005_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2016.08.005_bib3","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/JCO.2014.57.1745","article-title":"Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"33","author":"Dang","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2016.08.005_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2016.08.005_bib5","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2016.08.005_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.508","article-title":"Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET)","volume":"33","author":"Chan","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2016.08.005_bib7","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00280-013-2262-2","article-title":"Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study","volume":"72","author":"Jankowitz","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clbc.2016.08.005_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.critrevonc.2013.11.008","article-title":"Targeted therapy-induced diarrhea: a review of the literature","volume":"90","author":"Pessi","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clbc.2016.08.005_bib9","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(14)70006-3","article-title":"Guidance on the management of diarrhoea during cancer chemotherapy","volume":"15","author":"Andreyev","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2016.08.005_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3747\/co.21.2241","article-title":"Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors","volume":"21","author":"Hirsh","year":"2014","journal-title":"Curr Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clbc.2016.08.005_bib11","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.3747\/co.19.1054","article-title":"Supportive care treatments for toxicities of anti-EGFR and other targeted agents","volume":"19","author":"Melosky","year":"2012","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clbc.2016.08.005_bib12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ctrv.2015.05.011","article-title":"ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: chloride secretion as a mechanistic hypothesis","volume":"41","author":"Van Sebille","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clbc.2016.08.005_bib13","first-page":"56","article-title":"Blood of the dragon","volume":"84","author":"Lindner","year":"2009","journal-title":"HerbalGram"},{"key":"10.1016\/j.clbc.2016.08.005_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1310\/hct1406-261","article-title":"Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study","volume":"14","author":"Macarthur","year":"2013","journal-title":"HIV Clin Trials"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682091630235X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682091630235X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:15:08Z","timestamp":1761513308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682091630235X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S152682091630235X"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2016.08.005","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2016.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}